About Joseph Mullin
Form D filings for Bridge Therapeutics from 2018 to 2023 list Joseph Mullin as director.
Joseph Mullin first appears on SEC filings in 2018.
Experience
This experience comes from SEC filings. The years are when the filings name Joseph Mullin in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Joseph Mullin works with at each company, as listed on that company's latest Form D.
Bridge Therapeutics, Inc. · Form D, Dec 18, 2023
CP
Christopher Palutis
Director
EK
Elizabeth Kelley
Director
JB
Jason Bailey
Director
TP
Timothy Peara
President
JS
James Sullivan
Executive officer and director